Epigenetic control of somatostatin and cortistatin expression by β amyloid peptide

Journal of Neuroscience Research

Volumn 90, Issue 1, 2012, Pages 13-20

  Rubio, Alicia ^a   Sánchez Mut, José V ^b   García, Esther ^a   Velasquez, Zahady D ^a   Oliver, Jorge ^a   Esteller, Manel ^b,c   Avila, Jesús ^a,d  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Alzheimer's disease; GSK3; Histone methylation

Indexed keywords

AMYLOID BETA PROTEIN; CORTISTATIN; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE H3; LYSINE; MESSENGER RNA; SERINE; SOMATOSTATIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN NERVE CELL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPIGENETICS; HISTONE METHYLATION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

AMYLOID BETA-PEPTIDES; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; DRUG INTERACTIONS; EMBRYO, MAMMALIAN; EPIGENOMICS; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; MICE; MICE, INBRED C57BL; NEURONS; NEUROPEPTIDES; PHOSPHORYLATION; SERINE; SOMATOSTATIN; TUBULIN;

EID: 81255185496     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22731     Document Type: Article

References (39)

1. Allia E, Tarabra E, Volante M, Cerrato M, Ghigo E, Muccioli G, Papotti M. 2005. Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours. J Pathol 207: 336-345.
2. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. 1999. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett 453: 260-264.
3. Banker GA, Cowan WM. 1977. Rat hippocampal neurons in dispersed cell culture. Brain Res 126: 397-342.
4. Bayatti N, Zschocke J, Behl C. 2003. Brain region-specific neuroprotective action and signaling of corticotropin-releasing hormone in primary neurons. Endocrinology 144: 4051-4060.
5. Braun H, Schulz S, Becker A, Schroder H, Hollt V. 1998. Protective effects of cortistatin (CST-14) against kainate-induced neurotoxicity in rat brain. Brain Res 803: 54-60.
6. de Lecea L. 2008. Cortistatin-functions in the central nervous system. Mol Cell Endocrinol 286: 88-95.
7. de Lecea L, Castano JP. 2006. Cortistatin: not just another somatostatin analog. Nat Clin Pract Endocrinol Metab 2: 356-357.
8. de Lecea L, Criado JR, Prospero-Garcia O, Gautvik KM, Schweitzer P, Danielson PE, Dunlop CL, Siggins GR, Henriksen SJ, Sutcliffe JG. 1996. A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature 381: 242-245.
9. Deghenghi R, Papotti M, Ghigo E, Muccioli G. 2001. Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J Endocrinol Invest 24: RC1-RC3.
10. Epelbaum J, Guillou JL, Gastambide F, Hoyer D, Duron E, Viollet C. 2009. Somatostatin, Alzheimer's disease and cognition: an old story coming of age? Prog Neurobiol 89: 153-161.
11. Forloni G, Lucca E, Angeretti N, Chiesa R, Vezzani A. 1997. Neuroprotective effect of somatostatin on nonapoptotic NMDA-induced neuronal death: role of cyclic GMP. J Neurochem 68: 319-327.
12. Gahete MD, Rubio A, Duran-Prado M, Avila J, Luque RM, Castano JP. 2010. Expression of somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis 22: 819-828.
13. Geci C, How J, Alturaihi H, Kumar U. 2007. Beta-amyloid increases somatostatin expression in cultured cortical neurons. J Neurochem 101: 664-673.
14. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR. 1993. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 12: 803-808.
15. Jowaed A, Schmitt I, Kaut O, Wullner U. 2010. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 30: 6355-6359.
16. Justin N, De Marco V, Aasland R, Gamblin SJ. 2010. Reading, writing and editing methylated lysines on histone tails: new insights from recent structural studies. Curr Opin Struct Biol 20: 730-738.
17. Kiagiadaki F, Savvaki M, Thermos K. 2010. Activation of somatostatin receptor (sst 5) protects the rat retina from AMPA-induced neurotoxicity. Neuropharmacology 58: 297-303.
18. Kumar U. 2008. Somatostatin in medium-sized aspiny interneurons of striatum is responsible for their preservation in quinolinic acid and N-methyl-D-asparate-induced neurotoxicity. J Mol Neurosci 35: 345-354.
19. Lachner M, Jenuwein T. 2002. The many faces of histone lysine methylation. Curr Opin Cell Biol 14: 286-298.
20. Lee J, Ryu H. 2010. Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker? BMB Rep 43: 649-655.
21. Liu Z, Marquez M, Nilsson S, Holmberg AR. 2008. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. Oncol Rep 20: 151-154.
22. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V. 2006. A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Mol Cell 24: 627-633.
23. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. 2004. Gene regulation and DNA damage in the ageing human brain. Nature 429: 883-891.
24. Magdesian MH, Carvalho MM, Mendes FA, Saraiva LM, Juliano MA, Juliano L, Garcia-Abreu J, Ferreira ST. 2008. Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J Biol Chem 283: 9359-9368.
25. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82: 4245-4249.
26. Miller CA, Gavin CF, White JA, Parrish RR, Honasoge A, Yancey CR, Rivera IM, Rubio MD, Rumbaugh G, Sweatt JD. 2010. Cortical DNA methylation maintains remote memory. Nat Neurosci 13: 664-666.
27. Mukai F, Ishiguro K, Sano Y, Fujita SC. 2002. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem 81: 1073-1083.
28. Nothacker HP, Wang Z, Zeng H, Mahata SK, O'Connor DT, Civelli O. 2005. Proadrenomedullin N-terminal peptide and cortistatin activation of MrgX2 receptor is based on a common structural motif. Eur J Pharmacol 519: 191-193.
29. Pap M, Cooper GM. 1998. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 273: 19929-19932.
30. Popkie AP, Zeidner LC, Albrecht AM, D'Ippolito A, Eckardt S, Newsom DE, Groden J, Doble BW, Aronow B, McLaughlin KJ, White P, Phiel CJ. 2010. Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci. J Biol Chem 285: 41337-41347.
31. Robas N, Mead E, Fidock M. 2003. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J Biol Chem 278: 44400-44404.
32. Rubio A, Perez M, de Lecea L, Avila J. 2008. Effect of cortistatin on tau phosphorylation at Ser262 site. J Neurosci Res 86: 2462-2475.
33. Sadri-Vakili G, Cha JH. 2006. Mechanisms of disease: histone modifications in Huntington's disease. Nat Clin Pract 2: 330-338.
34. Siehler S, Nunn C, Hannon J, Feuerbach D, Hoyer D. 2008. Pharmacological profile of somatostatin and cortistatin receptors. Mol Cell Endocrinol 286: 26-34.
35. Soutar MP, Kim WY, Williamson R, Peggie M, Hastie CJ, McLauchlan H, Snider WD, Gordon-Weeks PR, Sutherland C. 2010. Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. J Neurochem 115: 974-983.
36. Supnet C, Bezprozvanny I. 2010. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 47: 183-189.
37. Torrisani J, Hanoun N, Laurell H, Lopez F, Maoret JJ, Souque A, Susini C, Cordelier P, Buscail L. 2008. Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. Endocrinology 149: 3137-3147.
38. Townsend M, Mehta T, Selkoe DJ. 2007. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282: 33305-33312.
39. Woodgett JR. 1990. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBOJ 9: 2431-2438.